Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vaxcyte, Inc.
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
March 23, 2026
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 11, 2026
Vaxcyte Announces Pricing of $550 Million Public Offering
January 29, 2026
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 26, 2026
←
Previous Page
1
2